Xenon Pharmaceuticals (XENE) Misses Q2 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. WDC
3. RNG
4. BYD
5. FIX
6. SPOT
7. BE
8. FCNCA
9. TSCO
10. WCN

Go back to Xenon Pharmaceuticals (XENE) Misses Q2 EPS by 3c

Xenon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

August 11, 2021 4:01 PM EDT

Topline Data from XEN1101 Phase 2b X-TOLE Clinical Trial Anticipated Late September to Mid-October 2021

Conference Call at 4:30 pm ET Today

BURNABY, British Columbia, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neurology-focused biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

Mr. Ian Mortimer, Xenons President and Chief Executive Officer stated, We continue to make strong progress across our portfolio of proprietary and partnered... More